Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-Hepatobiliary substudy 2 in advanced biliary tract cancer
CTR20232355Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rilvegostomig and volrustomig in biliary cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Safety and tolerability. Started Aug 2023; status: active.
02
Drugs
rilvegostomigvolrustomig
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20232355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232355.